Welcome to our dedicated page for Prime Medicine SEC filings (Ticker: PRME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Prime Medicine's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Prime Medicine's regulatory disclosures and financial reporting.
Prime Medicine (PRME) – Q2 2025 10-Q Snapshot
- Revenue: $1.1 m collaboration revenue (none in Q2 24); H1 revenue $2.6 m (+335% YoY).
- Expenses: R&D $41.4 m (-4% YoY); G&A $13.1 m (+4%). Total op-ex $54.5 m; loss from operations $53.4 m.
- Net loss: $52.6 m or $0.41/sh vs $55.3 m ($0.46) prior-year; H1 loss $104.5 m.
- Liquidity: Cash & cash equivalents $53.8 m (-70% YTD); investments $48.0 m; total liquid resources $101.8 m. Post-period Aug-25 equity raise added net $138.2 m, giving management >12-month runway.
- Balance sheet shifts: Right-of-use assets up to $120.2 m and non-current lease liabilities to $112.5 m following new Cambridge & Watertown facilities. Stockholders’ equity fell to $60.9 m (vs $153.1 m YE24) on continuing losses.
- Strategic updates: Focus pivots to in-vivo liver programs (Wilson’s, AATD) targeting INDs 1H-26; additional $24 m funding commitment from Cystic Fibrosis Foundation, incl. $6 m equity.
- Risks: Ongoing arbitration with Beam Therapeutics over AATD program could impose damages or halt development; high cash burn (~$90 m H1) and dilution from stock issuance remain concerns.
Management believes current cash plus August offering funds operations through at least Q3 26 while programs advance toward first clinical filings.
Chief Technical Officer Ann L. Lee filed a Form 4 showing a one-time repricing of 361,990 stock options originally granted under Prime Medicine’s 2019 and 2022 equity plans. On 08-01-2025 shareholders approved lowering the exercise price of the affected options from $12.30 and $8.49 to $4.04, the closing share price on the repricing date.
- Each original grant (180,995 options expiring 03-31-2033 and 180,995 options expiring 02-21-2034) was cancelled (coded “D”) and immediately re-granted (coded “A”) at the new strike.
- No change in the total number of options or underlying common shares; ownership remains 361,990 options, direct.
- All other terms, including vesting schedules, remain unchanged.
The filing signals management’s desire to restore the retention and incentive value of underwater options after PRME’s share price decline. While it is cash-neutral and non-dilutive today, repricing can draw shareholder-rights scrutiny because it rewards executives for past price under-performance without imposing new performance hurdles.
Prime Medicine (PRME) Form 4: Director Thomas Cahill reported a one-time repricing of four previously granted stock-option blocks on 08/01/2025. Options carrying exercise prices of $14.83 (39,062 shares) and $7.68 (45,000 shares) were cancelled (Code D) and simultaneously re-granted at $4.04 (Code A) for identical share amounts and original expirations (06/14/2033 and 06/12/2034, respectively). The new price equals PRME’s Nasdaq closing price on the repricing date, as approved by stockholders under the 2019 and 2022 equity plans. All vesting schedules and terms remain unchanged. Following the transactions, Cahill beneficially owns 84,062 options at the reduced strike, all held directly.
No open-market share movement or cash consideration occurred; the filing solely reflects the governance-approved adjustment intended to restore incentive value after a share-price decline.